Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Adverse events (As) of medicines are becoming a more serious problem of health care and society due to the growth of the pharmaceutical market. Incomplete information about AEs of drug therapy is an important aspect of this problem. The use of the register method is very promising in the study of adverse drug reactions in clinical practice. Aim. To study the AEs of drug therapy in the PROFILE outpatient register. Material and methods. Primary patients (n=1531) were included into the PROFILE outpatient register from January 2011 to August 2015. The median age of patients was 63 (54; 71) years. The registration card of patients and patient questionnaires were used within the register for the database creation. Analysis of retrospective data of the register was fulfilled Results. Various AEs were reported in 223 (14.6%) patients. Total anamnestic information on 301 cases of AEs was collected: 223 cases were recorded once, 63 – twice, 15 – three times. Patients with AEs were older than patients without AEs ((p<0.0001). AEs were registered most frequently in the use of ACE inhibitors and acetylsalicylic acid: an average of 15% of all cases, each. Various allergic reactions and symptoms of gastrointestinal disorders (pain, nausea, vomiting, diarrhea, etc.) were leaders in the structure of AEs. Naturally there were more patients without AEs among those, who did not take medications. Among patients treated with 6 to 10 medications per day, there were 1.5 times more people who had at least one AE (p<0.0001). Conclusion. The use of the register method allows to add information about the safety of various drugs. However, analysis of the prospective data of the PROFILE register looks the most promising for the solution of this problem.

About the Authors

Yu. V. Lukina
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation

N. A. Dmitrieva
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation

A. V. Zakharova
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation

A. V. Zagrebelnyy
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation

N. P. Kutishenko
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation

S. Yu. Martsevich
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation


1. Dorovskoi AV. Segments of the global pharmaceutical market: trends and contradictions. Biznes-Inform 2014, 9: 34-40. In Russian (Доровской А. В. Сегменты мирового фармацевтического рынка: тенденции и противоречия развития. Бизнес-информ; 2014, 9: 34-40).

2. Nalimov PA, Rudenko DJ. The global pharmaceutical market: the polarity of global health. EKO (vserossiyskiy ekonomicheskiy zhurnal) 2015; 3: 116-28. In Russian (Налимов П.А. Руденко Д.Ю. Мировой фармацевтический рынок: полярность глобального здоровья. ЭКО (всероссийский экономический журнал) 2015, 3: 116-28).

3. Moore TJ1, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167(16):1752-9

4. Wysowski DK, Swartz L Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005;165(12):1363-9.

5. The Russian pharmaceutical market. Issue January 2015. Moscow: DSM group; 2015. In Russian (Фармацевтический рынок России. Выпуск январь 2015. М.: DSM group; 2015).

6. WesterK, JönssonAK, SpigsetO, DruidH, HäggS. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 2008; 65: 573-9.

7. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5.

8. Breckenridge A. The burden of adverse drug events. Br J Clin Pharmacol 2015; 80: 785-87.

9. Saedder EA, Lisby M, Nielsen LP, Bonnerup DK, Brock B. Number of drugs most frequently found to be independent risk factors for serious adverse reactions: a systematic literature review. Br J Clin Pharma-col 2015;80(4):808-17.

10. Makary MA, Daniel M. Medical error—the third leading cause of death in the US. BMJ 2016; 353: i2139.

11. Rieder M, Ferro A. Adverse drug reactions. Br J Clin Pharmacol 2015;80(4):613-4.

12. FDA. Reports Received and Reports Entered into FAERS by Year. (As of November 2015) Available at Checked by 17.06.2016.

13. Lepahin VK, Sturov NV, Astakhova AV. Methods of identification and registration of adverse drug reactions during their widespread use. Trudnii Patsient 2008; 9: 42-6. In Russian (Лепахин В.К., Стуров Н.В., Астахова А.В. Методы выявления и регистрации неблагоприятных побочных реакций на лекарственные средства в период их широкого применения. Трудный Пациент 2008; 9: 42-6).

14. Astakhova AV, Lepahin VK. Medications. Adverse side effects and safety control. Moscow: Eksmo; 2008. In Russian (Астахова А.В., Лепахин В.К. Лекарства. Неблагоприятные побочные реакции и контроль безопасности. М.: Эксмо; 2008).

15. Norris S., Atkins D., Bruening W. et al. Selecting Observational Studies for Comparing Medical Interventions. Available at p:// ehc/products/196/454/ Methods-GuideNorris_06042010.pdf. Checked by 17.06.2016.

16. Gliklich R.E. Registries for Evaluating Patient Outcomes: A User’s Guide. Available at: Checked by 17.06.2016.

17. Martsevich SY, Drozdova LY, Kutishenko NP, Ginzburg ML. The registers as a way to study the effectiveness and safety of drugs. Klinitsist 2012; 3-4: 4-9. In Russian (Марцевич С.Ю., Дроздова Л.Ю., Кутишенко Н.П., Гинзбург М.Л. Регистры как способ изучения эффективности и безопасности лекарственных препаратов. Клиницист 2012; 3-4: 4-9).

18. Furberg CD., Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2(5): 205-7.

19. Topol E.J. Failing the public health — Rofecoxib, Merck, and the FDA. N Engl J Med 2004;351(17): 1707-9.

20. Psaty B. M., Furberg C.D. COX-2 inhibitors — Lessons in drug safety. N Engl J Med 2005;352(11): 1133-5.

21. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Medicine 2016; 14: 1-11.

22. Frank - aff-1 C, Himmelstein DU, Woolhandler S. et al. Era Of Faster FDA Drug Approval Has Also Seen Increased Black-Box Warnings And Market Withdrawals. Health Aff 2014; 33(8); 1453-9.

23. McNaughton R, Huet G, Shakir S. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making. BMJ Open 2014;4: e004221

24. Votchal BE. Sketches of Clinical Pharmacology. Moscow: Medicine; 1965. In Russian (Вотчал Б.Е. Очерки клинической фармакологии. М.: Медицина; 1965).

25. Guideline for Good Clinical Practice. 1996 Available at ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Checked by 17.06.2016.

26. Improving pharmacovigilance practice beyond spontaneous reporting. WHO Drug Information 2004; 18(3): 203-6.

27. Kukes VG, ed. Clinical pharmacology: a textbook for high schools. 4th edition. Moscow: GEOTAR Media; 2009. In Russian (Кукес В.Г., редактор. Клиническая фармакология: учебник для вузов. 4-е издание. М.: ГЭОТАР-Медиа; 2009).

28. Meyboom RHB, Lindquist M., Egberts ACG. An ABC of Drug-Related Problems. Drug Safety 2000; 22: 415-23.

29. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Safety 1994, 10:93-102.

30. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol Ther 1981; 30 (2): 239-45.

31. Rutberg H, Risberg MB, Sjödahl R. et al. Characterisations of adverse events detected in a university hospital: a 4-year study using the Global Trigger Tool method. BMJ Open 2014;4:e004879.

32. Classen DC, Resar R, Griffin F., et al. ‘Global Trigger Tool’ Shows That Adverse Events In Hospitals May Be Ten Times Greater Than Previously Measured. Health affairs. 2011; 30(4): 58

33. Belousov YB, Moiseyev VS, Lepahin VK. Clinical Pharmacology and Pharmacotherapy: A Guide for Physicians. Moscow: Universum; 1993. In Russin (Белоусов Ю.Б., Моисеев В.С., Лепахин В.К. Клиническая фармакология и фармакотерапия: Руководство для врачей. М.: Универсум; 1993).

34. Cunningham G., Dodd T.R., Grant D.J., McMurdo M.E., Richards R.M. Drug-related problems in elderly patients admitted to Tayside hospitals, methods for prevention and subsequent reassessment. Age Ageing 1997; 26(5): 375-82.

35. Furniss L. Use of medicines in nursing homes for older people. Advances in Psychiatric Treatment,2002, 8: 198-204

36. Mannesse C.K., Derkx F.H., de Ridder M.A., et al. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing 2000; 29 (1): 35-9.

37. Sánchez Muñoz-Torrero JF, Barquilla P, Velasco R et al. Adverse drug reactions in internal medicine units and associated risk factors. Eur J ClinPharmacol 2010;66(12):1257-64.

38. Passarelli MC, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging 2005;22(9):767-77.

39. Camargo AL1, Cardoso Ferreira MB, Heineck I. Adverse drug reactions: a cohort study in internal medicine units at a university hospital. J ClinPharmacol 2006, 62(2):143-9.


For citations:

Lukina Yu.V., Dmitrieva N.A., Zakharova A.V., Zagrebelnyy A.V., Kutishenko N.P., Martsevich S.Yu. ADVERSE EVENT OF DRUG THERAPY (THE FIRST RESULTS OF THE STUDY ACCORDING TO THE PROFILE OUTPATIENT REGISTER). Rational Pharmacotherapy in Cardiology. 2016;12(3):306-313.

Views: 822

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)